State Street’s Cue Biopharma CUE Stock Holding History

State Street’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$41.2K	Hold	5,978	–	–	﹤0.01%	4150
2025 Q4	$54.8K	Sell	5,978 -347	-5%	-$6.38K	﹤0.01%	4138
2025 Q3	$136K	Hold	6,325	–	–	﹤0.01%	3993
2025 Q2	$129K	Hold	6,325	–	–	﹤0.01%	3928
2025 Q1	$173K	Hold	6,325	–	–	﹤0.01%	3860
2024 Q4	$207K	Buy	6,325 +423	+7%	+$15.9K	﹤0.01%	3844
2024 Q3	$134K	Hold	5,902	–	–	﹤0.01%	3919
2024 Q2	$220K	Sell	5,902 -19,425	-77%	-$961K	﹤0.01%	3790
2024 Q1	$1.44M	Buy	25,327 +2,537	+11%	+$179K	﹤0.01%	3381
2023 Q4	$1.8M	Sell	22,790 -483	-2%	-$34.5K	﹤0.01%	3343
2023 Q3	$1.61M	Buy	23,273 +1,563	+7%	+$153K	﹤0.01%	3413
2023 Q2	$2.38M	Buy	21,710 +17,005	+361%	+$2M	﹤0.01%	3334
2023 Q1	$504K	Hold	4,705	–	–	﹤0.01%	3745
2022 Q4	$402K	Hold	4,705	–	–	﹤0.01%	3845
2022 Q3	$315K	Sell	4,705 -582	-11%	-$50.1K	﹤0.01%	3948
2022 Q2	$395K	Sell	5,287 -18,947	-78%	-$2.22M	﹤0.01%	3930
2022 Q1	$3.55M	Sell	24,234 -31,174	-56%	-$6.61M	﹤0.01%	3336
2021 Q4	$18.8M	Buy	55,408 +11,860	+27%	+$4.59M	﹤0.01%	2515
2021 Q3	$19M	Sell	43,548 -5,455	-11%	-$1.9M	﹤0.01%	2516
2021 Q2	$17.1M	Buy	49,003 +3,316	+7%	+$1.29M	﹤0.01%	2594
2021 Q1	$16.7M	Sell	45,687 -699	-2%	-$288K	﹤0.01%	2474
2020 Q4	$17.4M	Buy	46,386 +1,277	+3%	+$510K	﹤0.01%	2320
2020 Q3	$20.4M	Buy	45,109 +10,880	+32%	+$6.27M	﹤0.01%	2029
2020 Q2	$25.2M	Buy	34,229 +21,836	+176%	+$15.8M	﹤0.01%	1910
2020 Q1	$5.28M	Buy	12,393 +1,270	+11%	+$616K	﹤0.01%	2599
2019 Q4	$5.3M	Buy	11,123 +1,592	+17%	+$500K	﹤0.01%	2816
2019 Q3	$2.41M	Sell	9,531 -82	-0.9%	-$19.7K	﹤0.01%	3148
2019 Q2	$2.59M	Buy	9,613 +860	+10%	+$214K	﹤0.01%	3138
2019 Q1	$2.03M	Sell	8,753 -392	-4%	-$74.6K	﹤0.01%	3140
2018 Q4	$1.29M	Buy	9,145 +179	+2%	+$32.5K	﹤0.01%	3263
2018 Q3	$2.43M	Buy	8,966 +1,718	+24%	+$496K	﹤0.01%	3174
2018 Q2	$2.58M	Buy	7,248 +3,314	+84%	+$1.32M	﹤0.01%	3155
2018 Q1	$1.66M	Buy	+3,934	New	+$1.79M	﹤0.01%	3229

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

GWMR

GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCBWMS

Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return

AWM

Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

State Street's CUE Position: Q1 2026 in Review

State Street held its Cue Biopharma (CUE) position steady in Q1 2026 at 5,978 shares worth $41.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4150.

State Street first reported a position in CUE in Q1 2018 and has held it in 33 quarters since. The position peaked at $25.2M in Q2 2020. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

State Street held 5,978 shares of Cue Biopharma worth $41.2K as of Q1 2026.
State Street left its Cue Biopharma share count unchanged in Q1 2026.
Cue Biopharma made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4150 holding.
State Street first reported a position in Cue Biopharma in Q1 2018 and has held it in 33 quarters since.
State Street's Cue Biopharma position peaked at $25.2M in Q2 2020.
55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.